Results of GRAIL's Galleri Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology
Here's How Much $1000 Invested In Illumina 20 Years Ago Would Be Worth Today
Illumina Price Target Announced at $150.00/Share by Argus Research
Argus Research Upgrades Illumina(ILMN.US) to Buy Rating, Announces Target Price $150
Illumina's TruSight Oncology Biomarker Test Gets FDA Approval
Express News | Illumina: Tso Comprehensive Will Begin Shipping to Customers This Year
FDA Approves Illumina Cancer Biomarker Test With Two Companion Diagnostics to Rapidly Match Patients to Targeted Therapies
Is the Options Market Predicting a Spike in Illumina (ILMN) Stock?
Stocks With Three Weeks of Improving Technicals by Piper Sandler
S&P 500, Nasdaq 100 Extend 8-Session Winning Streak As Wall Street Jitters 'Go Poof': Monday's Key Stock Movers
Small-cap and Mid-cap Health Care Has Room to Rally - Roth MKM
This HP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Alibaba To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Friday
Daiwa Initiates Illumina(ILMN.US) With Buy Rating, Announces Target Price $154
Express News | Daiwa Capital Upgrades Illumina to Buy, Raises Price Target to $154
Illumina Inc.: Balancing Strong Market Potential Against Near-Term Uncertainties
Illumina Is Maintained at Sector Outperform by Scotiabank
Corvex Management Q2 Moves Include Exiting Air Products, TKO After Just One Quarter
Scotiabank Maintains Illumina(ILMN.US) With Buy Rating, Cuts Target Price to $164